Incyte’s Hem/Oncology Revenues Surge 107% and Monjuvi Phase III Success Paves H1 2026 Filing
Incyte’s Hematology/Oncology portfolio revenues surged 107% year-over-year in Q3 2025 driven by Monjuvi, Minjuvi, and Niktimvo sales. Positive Phase III frontMIND Monjuvi/rituximab data met primary and key secondary endpoints and supports a first-line DLBCL sBLA filing in H1 2026, potentially expanding the drug’s addressable market.
1. Hematology and Oncology Portfolio Drives Double-Digit Growth
Incyte’s Hematology and Oncology franchise delivered a 107% year-over-year revenue increase in Q3 2025, propelled primarily by robust uptake of Monjuvi/Minjuvi and expanding sales of Niktimvo. Monjuvi/Minjuvi contributed approximately 60% of the segment’s quarterly sales, reflecting continued market penetration in relapsed and refractory follicular lymphoma. Niktimvo revenues grew 85% versus the prior year, supported by new reimbursement agreements in key European markets and expanding use in combination regimens for myelofibrosis.
2. FrontMIND Phase III Data Unlocks First-Line DLBCL Opportunity
Positive results from the pivotal frontMIND study demonstrated that adding Monjuvi to standard R-CHOP therapy in first-line diffuse large B-cell lymphoma (DLBCL) achieved its primary endpoint of progression-free survival at 24 months, with a hazard ratio of 0.68 (p<0.001). Key secondary endpoints, including overall survival and complete response rate, also showed statistically significant improvements. These data support a supplemental Biologics License Application (sBLA) submission for first-line DLBCL in H1 2026, potentially expanding Incyte’s addressable market by an estimated $1.2 billion annually.
3. Upcoming Catalysts and Commercial Expansion
Looking ahead, Incyte expects additional readouts from its phase II RELYOND study of ruxolitinib plus TYK2 inhibitor in myeloproliferative neoplasms by Q2 2026. The company is preparing to launch Monjuvi in additional European Union markets following positive CHMP opinions. Management forecasts Hem/Oncology segment revenue growth of 45% for full-year 2026, driven by the first-line DLBCL filing, geographic expansion of Monjuvi/Minjuvi, and late-stage pipeline progress.
4. Balance Sheet and R&D Investment Support Sustained Innovation
Incyte closed Q3 2025 with cash, cash equivalents and marketable securities totaling $2.3 billion, covering more than two years of projected operating expenses. Research and development investment rose 22% year-over-year to $425 million in the quarter, reflecting intensified efforts in immuno-oncology and cytokine signaling programs. The strong balance sheet provides flexibility to advance internal pipeline assets and pursue strategic partnerships or acquisitions to bolster long-term growth.